ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Sanofi

Sanofi (SNY)

47.87
-0.62
( -1.28% )
Updated: 02:58:04

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
47.87
Bid
47.87
Offer
47.88
Volume
265,186
47.5701 Day's Range 48.1599
0.00 52 Week Range 0.00
Market Cap
Previous Close
48.49
Open
48.12
Last Trade
100
@
47.87
Last Trade Time
02:58:04
Financial Volume
US$ 12,703,719
VWAP
47.9049
Average Volume (3m)
-
Shares Outstanding
2,529,599,938
Dividend Yield
8.22%
PE Ratio
42.86
Earnings Per Share (EPS)
2.13
Revenue
43.07B
Net Profit
5.4B

About Sanofi

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company... Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. Show more

Sector
Health & Allied Services,nec
Industry
Pharmaceutical Preparations
Website
Headquarters
Paris, Paris, Fra
Founded
1994
Sanofi is listed in the Health & Allied Services sector of the NASDAQ with ticker SNY. The last closing price for Sanofi was US$48.49. Over the last year, Sanofi shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Sanofi currently has 2,529,599,938 shares in issue. The market capitalisation of Sanofi is US$122.66 billion. Sanofi has a price to earnings ratio (PE ratio) of 42.86.

SNY Latest News

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to...

L'immunisation par Beyfortus® pour protéger les nourrissons contre le VRS a commencé

L'immunisation par Beyfortus® pour protéger les nourrissons contre le VRS a commencé Canada NewsWire TORONTO, le 28 oct. 2024 Au Canada, six nouveau-nés sur 10 auront accès à...

Beyfortus® immunization to protect infants from RSV has begun

Beyfortus® immunization to protect infants from RSV has begun Canada NewsWire TORONTO, Oct. 28, 2024 Six out of 10 infants and newborns in Canada will have access to the protective antibody...

Capri Shares Crash 45% After Merger Block; Coursera Falls 18% on Lower Revenue Forecast

Tapestry (NYSE:TPR), Capri (NYSE:CPRI) – A U.S. judge blocked the $8.5 billion merger between Tapestry and Capri, favoring the Federal Trade Commission (FTC) and marking a win for the Biden...

Spirit’s Stock Surges 56% on Refinancing; Starboard Invests in Kenvue; Cigna-Humana Merger Back in Negotiations

Spirit Airlines (NYSE:SAVE) – Spirit Airlines managed to extend its $1.1 billion debt refinancing deadline by two months, until December 23, with the help of U.S. Bank. The company, which...

Sanofi and Orano Join Forces to Develop Next-generation Radioligand Medicines

Regulatory News: Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their...

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals PR Newswire BRIDGEWATER, N.J., Oct. 16, 2024 US FLUBLOK label1...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SNTISenti Biosciences Inc
US$ 13.80
(538.89%)
84.5M
PPBTPurple Biotech Ltd
US$ 13.43
(300.30%)
23.86M
JCSEJE Cleantech Holdings Limited
US$ 1.7812
(49.68%)
12.87M
PRZOParaZero Technologies Ltd
US$ 1.8301
(47.59%)
73.76M
FOSLFossil Group Inc
US$ 2.0899
(43.14%)
14.37M
MONDMondee Holdings Inc
US$ 0.362
(-49.03%)
867.79k
IDAIT Stamp Inc
US$ 0.525588
(-23.83%)
5.73M
QMCOQuantum Corporation
US$ 13.565
(-22.09%)
1.37M
LGHLWLion Group Holding Ltd
US$ 0.007
(-21.35%)
25.71k
INVZWInnoviz Technologies Ltd
US$ 0.0763
(-19.68%)
2.78k
XTIAXTI Aerospace Inc
US$ 0.04595
(2.34%)
128.11M
SMCISuper Micro Computer Inc
US$ 39.33
(20.50%)
94.35M
SNTISenti Biosciences Inc
US$ 13.79
(538.43%)
84.52M
RGTIRigetti Computing Inc
US$ 3.1207
(2.32%)
84.3M
PRZOParaZero Technologies Ltd
US$ 1.8201
(46.78%)
73.81M

SNY Discussion

View Posts
oldstocks oldstocks 10 months ago
Drug Companies making Epilepsy medication
MRNS $10.08
CERE $43.16
STOK $4.98
UCBJF $102.00
SNY $45.63
PFE $27.00
OTSUK $18.36
$RSPI .0013
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients

Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

https://pubmed.ncbi.nlm.nih.gov/35041859/

https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/

National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/

The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
https://www.sciencedirect.com/science/article/abs/pii/S000689931930410X
👍️0
TheFinalCD TheFinalCD 1 year ago
https://ih.advfn.com/stock-market/NASDAQ/first-wave-biopharma-FWBI/stock-news/92040537/form-8-k-current-report
👍️0
TheFinalCD TheFinalCD 2 years ago
https://finance.yahoo.com/m/808ec522-bbcd-3db0-a334-2d054dbf3797/sanofi-to-buy-provention-bio.html
👍️0
~Gordo~ ~Gordo~ 4 years ago
Took a position here...looking to hold awhile...
$SNY
👍️0
BottomBounce BottomBounce 4 years ago
$SNY Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

https://fool.com/investing/2020/12/16/why-astrazenecas-and-sanofis-bad-news-could-be-gre/
👍️0
whytestocks whytestocks 4 years ago
JUST IN: $SNY Is Novavax Stock a Buy?

The COVID-19 pandemic has affected daily life in a number of ways, and a vaccine for the disease is probably our best hope for a return to normal. Thankfully, well over a dozen companies are working to develop a vaccine for the novel coronavirus at an incredible pace; one of these, Novavax (N...

Got this from SNY - Is Novavax Stock a Buy?
👍️0
BottomBounce BottomBounce 5 years ago
Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
Collaboration


https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx
👍️0
Glider549 Glider549 5 years ago
Moncef Slaoui, a former GlaxoSmithKline   executive, will lead “Operation Warp Speed,” Trump’s push to accelerate the vaccine development process for COVID-19.
SNY partnered with GSK last April to make a Covid-19 vaccine.
Food for thought.
👍️0
chrispy2468 chrispy2468 5 years ago
Nice find.
👍️0
tw0122 tw0122 5 years ago

Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4

Provided by GlobeNewswire

Apr 27, 2020 9:30 AM EDT

WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been informed by researchers at the U.S. Regional Biocontainment Laboratory (RBL) that continued coronavirus (COVID-19) testing of Brilacidin, the Company’s defensin-mimetic drug candidate, is scheduled to begin the week of May 4.

👍️0
john1311 john1311 5 years ago
Sanofi warns Europe on Covid-19 vaccine

French pharma group has two candidates in pipeline

https://www.ft.com/content/5884987a-e1d1-476a-b538-368e2a915480

Sanofi would be able to deliver an effective vaccine within the next 18 months but warned that the bigger challenge would be ramping up production to meet potentially massive demand.

Sanofi Pasteur vaccine division employs about 10,000 people and has 12 factories globally. It has two Covid-19 vaccines in development: one of which is a traditional protein-based vaccine, and another known as an mRNA vaccine, which is a new type that promises to be faster to manufacture but remains as yet unproven.



Sanofi is also testing the efficacy of two of its drugs already approved for other uses against Covid-19, including the malaria drug hydroxychloroquine and Kevzara, which is usually used to treat rheumatoid arthritis. 

On Friday, the company confirmed its goal for earnings per share to rise 5 per cent this year, after reporting higher first-quarter sales and profits buoyed by people stockpiling its drugs during the Covid-19 outbreak. 

That first-quarter stockpiling boost will be “largely offset” by an expected slowdown in the second quarter.

Like-for-like revenue rose 6.6 per cent to €8.97bn in the quarter to March 30 driven by higher sales of over-the-counter medicines for pain and fever, and eczema drug Dupixent.

Net income rose 16.1 per cent to €2bn.


👍️0
tw0122 tw0122 5 years ago
Small Trial Suggests Antimalarial Drugs Not Effective For Treating Coronavirus

KATHERINE SELEY-RADTKE, THE CONVERSATION

6 APRIL 2020

On Saturday the Food and Drug Administration approved the use of two antimalarial drugs, hydroxychloroquine and a related medication, chloroquine, for emergency use to treat COVID-19. The drugs were touted by President Trump as a "game changer" for COVID-19.

However, a study just published in a French medical journal provides new evidence that hydroxychloroquine does not appear to help the immune system clear the coronavirus from the body.

The study comes on the heels of two others - one in France and one in China - that reported some benefits in the combination of hydroxychloroquine and azithromycin for COVID-19 patients who didn't have severe symptoms of the virus.

I am a medicinal chemist who has specialized in discovery and development of antiviral drugs for the past 30 years, and I have been actively working on coronaviruses for the past seven.

I am among a number of researchers who are concerned that this drug has been given too much of a high priority before there is enough evidence to show it is indeed effective.

There are already other clinical studies that showed it is not effective against COVID-19 as well as several other viruses. And, more importantly, it can have dangerous side effects, as well as giving people false hope.

The latter has led to widespread shortages of hydroxychloroquine for patients who need it to treat malaria, lupus and rheumatoid arthritis, the indications for which it was originally approved.

The idea that the combination of hydroxychloroquine with an antibiotic drug, azithromycin, was effective against COVID-19 gained more attention after a study published on March 17. This study described a trial of 80 patients carried out by Philippe Gautret in Marseille, France.

Although some of their results appeared to be encouraging, it should also be noted that most of their patients only had mild symptoms. Furthermore, 85 percent of the patients didn't even have a fever – one of the major telltale symptoms of the virus, thus suggesting that these patients likely would have naturally cleared the virus without any intervention.

In another study, posted on medRxiv, which has not yet been peer-reviewed, Chinese scientists from Renmin Hospital of Wuhan University, in Wuhan, China, gave hydroxychloroquine to patients with only mild infections who were free of medical issues, similar to the Gautret study. The results showed that the 31 patients who received the drug showed a lessening of their symptoms 24 hours earlier than patients in the control group.

In addition, pneumonia symptoms improved in 25 of the 31 patients versus 17 of 31 in the control group. As noted in several of the comments associated with the manuscript, there are issues related to the translation of the paper, thus clouding interpretations of some of the results. The paper also appears to focus more on pneumonia than COVID-19. However, these issues may be cleared up or addressed once the paper finishes the peer-review process.

But two other studies have conflicting results.

A second French group, led by Jean-Michel Molina, has now tested the hydroxychloroquine-azithromycin combination treatment in 11 patients at the Hôpital Saint-Louis in Paris, France, and their results were strikingly different.

Like the Marseille study, the Molina trial was also a small pilot study. Molina and colleagues used the same dosing regimen as Gautret. In contrast, however, to the Gautret study, eight of the 11 patients had underlying health conditions, and 10 of 11 had fevers and were quite ill at the time the dosing began.

These Paris researchers found that after five to six days of treatment with hydroxychloroquine (600 mg per day for 10 days) and azithromycin (500 mg on day 1 and 250 mg on days 2 to 5), eight of the 10 patients still tested positive for COVID-19.

Of these 10 patients, one patient died, two were transferred to the ICU and another had to be removed from the treatment due to serious complications.

In addition, a similar study in China also showed no difference in viral clearance after seven days either with or without the hydroxychloroquine with the patients in the trial. This supports Molina's findings.

Thus, despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.

As Molina and colleagues note: "Ongoing randomized clinical trials with hydroxychloroquine should provide a definitive answer regarding the alleged efficacy of this combination and will assess its safety."

Katherine Seley-Radtke, Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County.

👍️0
tw0122 tw0122 5 years ago
https://www.thedailybeast.com/trump-reportedly-has-financial-interest-in-hydroxychloroquine-manufacturer
👍️0
tw0122 tw0122 5 years ago
Malaria drug fails at hospital https://www.bloomberg.com/news/articles/2020-04-02/hyped-malaria-drug-not-showing-much-effect-at-one-paris-hospital
👍️0
QaB2i QaB2i 5 years ago
Yup. This is a trade for a flip
👍️0
john1311 john1311 5 years ago
Bought in here today...
👍️0
Glider549 Glider549 5 years ago
https://www.barrons.com/articles/coronavirus-covid-19-vaccine-program-51585341169?siteid=yhoof2&yptr=yahoo
👍️0
buysell101 buysell101 5 years ago
I think unfortunately because this is a Pharma stock now a biotech...sad I sold out today 30 min charts look toppy and thought this one would have already run...
👍️0
BOS BOS 5 years ago
I’m confused, I would of thought this would have moved more. What am I missing?
👍️0
Pt3 Pt3 5 years ago
is too late to join SNY SINCE VACCINE ALREADY APPROVE
👍️0
giveit2me giveit2me 5 years ago
pill instead of vaccine
👍️0
giveit2me giveit2me 5 years ago
i love SNY
👍️0
giveit2me giveit2me 5 years ago
hydroxychloroquine, market is slow, im fast
👍️0
buysell101 buysell101 5 years ago
FDA about to speak...bought some here just in case gl2all.
👍️0
ezyE ezyE 5 years ago
Goldman Sachs rate Sanofi a buy.
Working on several new drugs plus a vaccine for virus .
👍️0
whytestocks whytestocks 5 years ago
News: $SNY Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both

On Dec. 9, pharmaceutical giant Sanofi (NASDAQ: SNY)  said it's buying immuno-oncology company Synthorx (NASDAQ: THOR) for $2.5 billion to boost its cancer and autoimmune program.  Considering the performance of Sanofi's businesses, the pipeline Synthorx brings to the ...

Got this from SNY - Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
👍️0
whytestocks whytestocks 5 years ago
News: $SNY Here's Why Dermira Stock Popped Today

Shares of Dermira (NASDAQ: DERM) , a biopharmaceutical company, jumped at the beginning of today's trading session in response to good news from the Food and Drug Administration. Investors looking forward to a shortened review for the company's experimental eczema therapy drove the stock...

Find out more SNY - Here's Why Dermira Stock Popped Today
👍️0
stratford1 stratford1 5 years ago
Time for puts - Zantac getting pulled from shelves.
Looking for a return to near $40.
👍️0
whytestocks whytestocks 5 years ago
News: $SNY 2 Biotech Stocks I Wouldn't Touch With a Broom

Drug development is a losing game full of highly trained professionals who would rather be lucky than talented at their jobs. This is because experimental new drugs fail so frequently that an entire career without one successful new drug discovery under their belts isn't uncommon. Doing everyth...

Got this from SNY - 2 Biotech Stocks I Wouldn't Touch With a Broom
👍️0
Trend-Setter Trend-Setter 6 years ago
BioNTech Teams up With Sanofi to Target Solid Tumors in $91.5 Million Deal...

As part of the deal, the French pharma giant will invest about $91.5 million in equity in BioNTech, a privately-held company. The investment follows BioNTech’s 2018 decision to exercise one of the option rights under the 2015 agreement to co-develop and co-commercialize the immuno-oncology candidate. The two companies will work to develop an investigational therapy that includes an mRNA mixture encoding immunomodulatory cytokines that are injected directly into the tumor. Local administration of immunotherapies to the tumor microenvironment provides the opportunity to stimulate innate and adaptive immune responses against tumors, while potentially avoiding toxicities related to systemic administration of immuno-modulatory therapeutics.

https://www.biospace.com/article/biontech-teams-up-with-sanofi-to-target-solid-tumors-in-91-5-million-deal/
👍️0
Trend-Setter Trend-Setter 6 years ago
Keep an eye on this sleeper with so much potential- a potential M&A target. IMO

Mymetics Corp. (otcqb: MYMX)

Imminent Catalysts:

1) Collaboration with Sanofi Pasteur(vaccine unit of giant pharma Sanofi) will conclude this year's (2018) end. Successful outcome will lead to either exclusive licensing deal of Mymetics' proprietary VLP platform for use in Sanofi's influenza vaccines or buyout.

2) Collaboration with Anergis,SA which preclinical results expected at year's (2018) end or 1st Q of 2019. A successful outcome will lead to exclusive worldwide licensing deal with Mymetics' proprietary VLP platform for use in all of Anergis' allergy immunotherapy vaccines.

3) MACIVIVA(Manufacturing for cold chain independent virosome based vaccines) of which Mymetics is leading a consortium of 4 other companies including giant CMO Catalent(NYSE:CTLT) using Mymetics' HIV-1 vaccine will conclude this month of November 2018.

4) A possibility of advancing Mymetics' HIV-1 vaccine to Phase Ib - II under the framework of MACIVIVA project.



GLTA
👍️0
Trend-Setter Trend-Setter 6 years ago
Consortium partner tweeted:

"Upperton abstract, entitled Developing Cold Chain Independent Vaccines - Spray-drying of Virosomes to Produce Dry Powder Formulations, has been Accepted for Poster presentation at the 2018 AAPS Annual Meeting to be held November 4-7, 2018 in DC"

https://twitter.com/UppertonLtd/status/1020235017056923648
👍️0
Trend-Setter Trend-Setter 6 years ago
Under-the-Radar R&D Biotech microcap with so much potential!

>>>Mymetics(otcqb:MYMX) - Sanofi Pasteur [vaccine unit of Sanofi(nyse:SNY)]<<<
short term catalyst ~June 2018 collaboration result/decision point!

Mymetics' (OTCQB:MYMX) extremely undervalued @ $ 0.04

>>> Vaccine Pipeline:
HIV
Malaria
Intranasal Influenza
RSV
Chikungunya

>>> Partnerships:
Anergis ---------------------------------------------------------- April 2018 - present
Sanofi Pasteur (vaccine unit of Sanofi : NYSE: SNY) --- Oct.2016 - present
Astellas Pharma (2nd Largest Japanese Pharma Co.)-- Jan.2014 - July 2016
Catalent (NYSE:CTLT) ---April 2015 - Present
Bachem (SIX:BANB) ------April 2015 - Present
Upperton, UK -------------- April 2015 - Present
Chimera Biotec, Germany-April 2015 - Present
Texas Biomedical Research Institute - Sept.2014 - Present

>>> Funding Organizations:
Bill & Melinda Gates Foundation - HIV-1 vaccine
PATH MVI ------------------------------ Malaria Transmission Blocking Vaccine
Swiss Tropical & Public Health Institute --- Malaria Vaccine
European Union Horizon 2020---------------MACIVIVA (Manufacturing Process For Cold-Chain Independent Virosome based Vaccines)-- Mymetics is leading a consortium of 4 other companies.

**** MACIVIVA *****
>>> MACIVIVA = Game Changer = Disrupting the vaccine industry worldwide!
MACIVIVA latest Progress' Reporting Period Posted: https://cordis.europa.eu/result/rcn/194900_en.html
Copy of latest MACIVIVA presentation (downloadable): https://www.mymetics.com/media-center/world-vaccine-congress-10-12-october-2017-barcelona/

>>> No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
http://investor.catalent.com/press-release/financial-news/no-more-pricks-%E2%80%93-quick-dissolvable-tablet-set-disrupt-vaccine-industry https://vimeo.com/217946374<<< click video insert

>>> Dr. Christopher Henney, currently Anthera Pharmaceuticals(ANTH) and Cascadian Therapeutics (formerly Oncothyreon) - recently acquired by Seattle Genetics, Chairman of the Board; Director at Cyclacel Pharmaceuticals and former Dendreon co-founder & CEO was once on board with this unknown microcap as Chairman of BOD but seems had a disagreement with the largest shareholder that led him and his Dendreon protege to leave in less than a year.
https://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/

Share Structure:
Outstanding : 303.7million common shares (unchanged since 2014)
Float: ~ 91 million shares

>>> MYMX is leading this disruptive project.
https://cordis.europa.eu/docs/results/h2020/646/646122_PS/maciviva-project-concept.jpg

"click" on Company Overview: https://www.mymetics.com/about/


****taken from yahoo message board courtesy of nito****
👍️0
Trend-Setter Trend-Setter 7 years ago
April 16th 2018 - The Best Stock Investment For 2018 - Mymetics Corp. (MYMX)
https://askwarrenbuffet.blogspot.com/2018/02/the-best-investment-for-2018-is.html
👍️0
Trend-Setter Trend-Setter 7 years ago
Sanofi strikes again! 2nd acquisition deal this month. Who's Next?

"We can still do additional bolt on acquisitions," Chief Executive Olivier Brandicourt said on a call with reporters, adding that the company had a general target of EUR20 billion for acquisitions.

https://ih.advfn.com/p.php?pid=nmona&article=76572055

👍️0
Trend-Setter Trend-Setter 7 years ago
Microcap Mymetics Corp. (OTCQB:MYMX ) .03 on watch!

Partnerships:
Sanofi Pasteur (vaccine unit of Sanofi : NYSE: SNY) --- Oct.2016 - present
Astellas Pharma (2nd Largest Japanese Pharma Co.)-- Jan.2014 - July 2016
Catalent (NYSE:CTLT) ---April 2015 - Present
Bachem (SIX:BANB) ------April 2015 - Present
Upperton, UK -------------- April 2015 - Present
Chimera Biotec, Germany-April 2015 - Present
Texas Biomedical Research Institute - Sept.2014 - Present

Funding Organizations:
Bill & Melinda Gates Foundation - HIV-1 vaccine
PATH MVI ------------------------------ Malaria Transmission Blocking Vaccine
Swiss Tropical & Public Health Institute --- Malaria Vaccine
European Union Horizon 2020---------------MACIVIVA (Manufacturing Process For Cold-Chain Independent Virosome based Vaccines)--Mymetics is leading a consortium of 4 other companies.

"click" on Company Overview: https://www.mymetics.com/about/


*courtesy of nito from yahoo mymx message board*
https://finance.yahoo.com/quote/MYMX/community?p=MYMX
👍️0
zerowinner zerowinner 7 years ago
https://www.wsj.com/articles/sanofi-nears-deal-to-buy-hemophilia-drugmaker-bioverativ-for-more-than-11-5-billion-1516584141
👍️0
Trend-Setter Trend-Setter 7 years ago
A bump on the road but still going!
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4124256-sanofi-wants-make-major-footprint-multiple-sclerosis-space
👍️0
Trend-Setter Trend-Setter 7 years ago
SANOFI-MYMETICS collaboration result anytime now? Come on Mymetics bring the news!!! Will it be JV or Buyout???
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4109199-alnylam-sanofi-achieve-rnai-first
👍️0
Trend-Setter Trend-Setter 7 years ago
SANOFI-MYMETICS

https://insiderfinancial.com/heres-our-take-on-mymetics-corp-otcmktsmymx/146314/

👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4086761-alnylam-sanofi-produce-monster-alternative-hemophilia-market
👍️0
XtraFunds XtraFunds 8 years ago
Picked up a starter. Going long. $SNY
👍️0
Trend-Setter Trend-Setter 8 years ago
Sanofi working on intra-nasal Fluzone to compete with Aztra Zeneca's Flumist?

"There are a number of quadrivalent options for consumers to choose from this season. One option that is available -- but which the CDC suggests you steer clear -- is AstraZeneca's nasal spray FluMist. Despite being a handy alternative to getting a shot,studies have suggested that FluMist simply isn't effective compared to the other flu vaccines being offered"

https://www.fool.com/investing/2017/02/11/flu-death-rates-just-hit-the-epidemic-threshold-bu.aspx

http://finance.yahoo.com/news/mymetics-starts-research-project-sanofi-100000417.html

http://www.mymetics.com/
👍️0
Trend-Setter Trend-Setter 8 years ago
"In 2017 and beyond we will continue to simplify and reshape the company," Chief Executive Oliver Brandicourt told journalists. "We will be supported by our current growth engine businesses: Sanofi Genzyme, vaccines and consumer healthcare".

http://finance.yahoo.com/news/drugmaker-sanofi-sees-weak-2017-082546194.html



The keyword is SIMPLIFY and that's exactly the partnership is all about. IMO, Sanofi is aiming of simplifying the old and traditional method of making their virus-based vaccines to reduce costs as well as improving effectiveness of their vaccines not to mention the broad range application of Mymetics' virosome-based VLP platform.

Is Mymetics the next acquisition target?
👍️0
Trend-Setter Trend-Setter 8 years ago
"In 2017 and beyond we will continue to simplify and reshape the company," Chief Executive Oliver Brandicourt told journalists. "We will be supported by our current growth engine businesses: Sanofi Genzyme, vaccines and consumer healthcare".

http://finance.yahoo.com/news/drugmaker-sanofi-sees-weak-2017-082546194.html



The keyword is SIMPLIFY and that's exactly the partnership is all about. IMO, Sanofi is aiming of simplifying the old and traditional method of making their virus-based vaccines to reduce costs as well as improving effectiveness of their vaccines not to mention the broad range application of Mymetics' virosome-based VLP platform.

Is Mymetics the next acquisition target?
👍️0
remind2 remind2 8 years ago
SNY & Tiny $GOVX @ .06, $3.2M market cap featured in Zika article.

Feb 1, 2017:

Link:
http://www.pharmavoice.com/article/2017-2-zika-research/
👍️0
Trend-Setter Trend-Setter 8 years ago
Sanofi and Mymetics Corp. (otcbb:MYMX) partners for virosome influenza vaccine. The project is to evaluate influenza vaccines based on Mymetics' proprietary Virus Like Particle(VLP) technology platform versus Egg-based split vaccines.

http://ih.advfn.com/p.php?pid=nmona&article=73038267


Mymetics website: http://www.mymetics.com/
👍️0
venturecapp venturecapp 8 years ago
Sanofi Adds Costa Rica To Dengvaxia Approval List

http://marketexclusive.com/sanofi-sa-nysesny-adds-costa-rica-dengvaxia-approval-list/8377/?icd1
👍️0